TFE3
TFE3 (Transcription factor E3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma, Sarcomas, Colorectal cancer and 1 more.
Overview
Transcription factor that acts as a master regulator of lysosomal biogenesis and immune response. Specifically recognises and binds E-box sequences (5'-CANNTG-3'); efficient DNA-binding requires dimerisation with itself or with another MiT/TFE family member such as TFEB or MITF. Involved in the cellular response to amino acid availability by acting downstream of MTOR: in the presence of nutrients, TFE3 phosphorylation by MTOR promotes its inactivation.
Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.99, genetic association 0.64, somatic mutation 0.98, genetic literature 0.76). In OnCo, 1 product record names it (Cediranib).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · TFE3 (Transcription factor E3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma, Sarcomas, Colorectal cancer and 1 more.
- 1 · What it is
TFE3 (Transcription factor E3) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a fusion partner, and the evidence so far is association rather than a proven role. Tied to Renal cell carcinoma, Sarcomas, Colorectal cancer and 1 more.
- 2 · What goes wrong in cancer
Transcription factor that acts as a master regulator of lysosomal biogenesis and immune response.
- 3 · How drugs use it
No product in this corpus aims at TFE3 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:11752 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P19532 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000068323 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: colorectal cancer 0.50, renal cell carcinoma 0.66, melanoma 0.52, sarcoma 0.57 (GraphQL API, CC0))
Biology
Transcription factor that acts as a master regulator of lysosomal biogenesis and immune response. Specifically recognises and binds E-box sequences (5'-CANNTG-3'); efficient DNA-binding requires dimerisation with itself or with another MiT/TFE family member such as TFEB or MITF. Involved in the cellular response to amino acid availability by acting downstream of MTOR: in the presence of nutrients, TFE3 phosphorylation by MTOR promotes its inactivation. Upon starvation or lysosomal stress, inhibition of MTOR induces TFE3 dephosphorylation, resulting in transcription factor activity. Specifically recognises and binds the CLEAR-box sequence (5'-GTCACGTGAC-3') present in the regulatory region of many lysosomal genes, leading to activate their expression, thereby playing a central role in expression of lysosomal genes. Maintains the pluripotent state of embryonic stem cells by promoting the expression of genes such as ESRRB; mTOR-dependent TFE3 cytosolic retention and inactivation promotes exit from pluripotency. Location: Cytoplasm, cytosol; Nucleus; Lysosome membrane (UniProt). Locus Xp11.23 (HGNC).
- Renal cell carcinoma: Open Targets association 0.66 with renal cell carcinoma (MONDO_0005086)
- Sarcomas: Open Targets association 0.57 with sarcoma (MONDO_0005089)
- Colorectal cancer: Open Targets association 0.50 with colorectal cancer (MONDO_0005575)
- Melanoma: Open Targets association 0.52 with melanoma (MONDO_0005105)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: 1 OnCo product record names it; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "association-only" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"TFE3" OR ABSTRACT:"TFE3" OR TITLE:"transcription factor binding to IGHM enhancer 3" OR ABSTRACT:"transcription factor binding to IGHM enhancer 3" OR TITLE:"Transcription factor E3" OR ABSTRACT:"Transcription factor E3" OR TITLE:"bHLHe33" OR ABSTRACT:"bHLHe33") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TFE3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetASPSCR1
Shares Cediranib, Sarcomas (soft tissue, bone, GIST), Open Targets Platform.
- TrialCediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Shares Cediranib, Colorectal cancer.
- TreatmentPazopanib
Shares Cediranib, Renal cell carcinoma, Sarcomas (soft tissue, bone, GIST).
- CancerAlveolar soft part sarcoma
- TreatmentAnlotinib